Results 11 to 20 of about 3,769,586 (361)

Peptides, Antibodies, Peptide Antibodies and More [PDF]

International Journal of Molecular Sciences, 2019
The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of ...
Nicole Trier, Paul Hansen, Gunnar Houen
openaire   +5 more sources

Acknowledgment to Reviewers of Antibodies in 2020

Antibodies, 2021
Peer review is the driving force of journal development, and reviewers are gatekeepers who ensure that Antibodies maintains its standards for the high quality of its published papers [...]
Antibodies Editorial Office
doaj   +1 more source

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fangzhu Zhao, Deli Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, C. Smith, G. Song, J. Woehl, Linlin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, Stephen A. Rawlings, N. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. Wilson, R. Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Science, 2020
An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al.
A. Baum, Benjamin O. Fulton, Elzbieta Wloga, R. Copin, Kristen E. Pascal, Vincenzo Russo, Stephanie Giordano, Kathryn Lanza, N. Negron, M. Ni, Yi Wei, G. Atwal, A. Murphy, N. Stahl, G. Yancopoulos, C. Kyratsous   +15 more
semanticscholar   +1 more source

Antibodies and antibody-derived analytical biosensors [PDF]

Essays in Biochemistry, 2016
The rapid diagnosis of many diseases and timely initiation of appropriate treatment are critical determinants that promote optimal clinical outcomes and general public health. Biosensors are now being applied for rapid diagnostics due to their capacity for point-of-care use with minimum need for operator input.
Hannah Byrne, Richard O'Kennedy, Shikha Sharma   +2 more
openaire   +3 more sources

Development of therapeutic antibodies for the treatment of diseases

Journal of Biomedical Sciences, 2020
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved.
Ruei-Min Lu, Yu-Chyi Hwang, I. Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han‐Chung Wu   +6 more
semanticscholar   +1 more source

Antibodies and tuberculosis

Tuberculosis, 2016
Tuberculosis (TB) remains a major public health problem internationally, causing 9.6 million new cases and 1.5 million deaths worldwide in 2014. The Bacillus Calmette-Guérin vaccine is the only licensed vaccine against TB, but its protective effect does not extend to controlling the development of infectious pulmonary disease in adults. The development
Gavin R. Screaton, Robert J. Wilkinson, Ashley Jacobs, Ashley Jacobs, Juthathip Mongkolsapaya, Helen McShane   +5 more
openaire   +5 more sources

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Nature Communications, 2021
Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear.
Allison J. Greaney, Tyler N. Starr, C. Barnes, Y. Weisblum, F. Schmidt, M. Caskey, C. Gaebler, A. Cho, Marianna Agudelo, Shlomo Finkin, Zijun Wang, D. Poston, F. Muecksch, T. Hatziioannou, P. Bieniasz, D. Robbiani, M. Nussenzweig, P. Bjorkman, J. Bloom   +18 more
semanticscholar   +1 more source